AVTX-010 — IND submission
H1 2027
Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with IND submission planned for the first half of 2027Source filing
AVTX biotech catalysts & pipeline
AVALO THERAPEUTICS INC · Data as of 2026-09-08